Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
HORIZON MEDICINES LLC et al v. DR. REDDY'S LABORATORIES INC. et al
Case Number:
2:15-cv-03324
Court:
Nature of Suit:
Judge:
Firms
- ArentFox Schiff
- FisherBroyles
- Fox Rothschild
- McCarter & English
- Pergament & Cepeda
- Rivkin Radler
- Windels Marx
Companies
Sectors & Industries:
-
February 25, 2022
NJ Judge Scraps Claims In 2 Horizon Drug Patents
A federal judge in New Jersey has ruled that claims in two Horizon Pharma patents that cover the arthritis drug Vimovo never should have been issued in the first place, sinking an infringement suit against Dr. Reddy's Laboratories that had been rattling around for half a decade.
-
November 08, 2019
Dr. Reddy's Can't Kill Arthritis Drug Patent Suit Yet
A New Jersey federal judge refused Dr. Reddy's Laboratories Inc.'s bid to invalidate two of Horizon Pharma Inc.'s patents for arthritis drug Vimovo, ruling Thursday that the generic-drug maker hasn't shown the patents lack an adequate written description.
-
November 20, 2018
Dr. Reddy's, Mylan Win Challenge To Arthritis Drug Patents
A New Jersey federal judge on Monday invalidated patents covering Horizon Pharma Inc.'s arthritis drug Vimovo in its suit against Dr. Reddy's Laboratories Inc. and Mylan Pharmaceuticals Inc. over their plans to manufacture and market generic versions, finding a claim term in the patents to be indefinite.